MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

0
Player Avatar cmrk3 (42.87) Submitted: 7/4/2012 11:17:31 AM : Outperform Start Price: $2.66 MNKD Score: +3.13

Affrezza is likely to be approved.

Featured Broker Partners


Advertisement